|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.94 USD | +1.98% |
|
-14.32% | +38.25% |
| 05-09 | ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-07 | ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment | MT |
ImmunityBio, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.04 million compared to USD 0.36 million a year ago. Net loss was USD 134.11 million compared to USD 116.34 million a year ago.
Basic loss per share from continuing operations was USD 0.2 compared to USD 0.27 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +38.25% | 4.8B | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.12% | 21.97B | |
| -4.64% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
IMMUNITYBIO, INC. 
